Previous 10 | Next 10 |
Success is not final; failure is not fatal: it is the courage to continue that counts. - Winston Churchill Not all companies are scared of a drug losing patent protection. Generics are drugs identical in chemical composition to the original medicines, and hence, rely heavily on the e...
This article was written by Edward Mwangi and Jacques Georget Opportunity Summary Mylan’s merger with Pfizer’s Upjohn division, which almost exclusively offers generic drugs, will provide an addition to the product portfolio. It will also provide new capital to finance inno...
The past year has been great for stocks across the board, but that's made it awfully hard to find reliable dividend-paying stocks that offer satisfactory yields. The average dividend yield for stocks in the S&P 500 index has dwindled to just 1.8% at the moment, but there are stil...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Markets are looking to celebrate a different Christmas Eve than the one last year, which saw the S&P 500 dip into bear market...
Introduction I recently wrote an article about Revance Therapeutics' ( RVNC ) long-acting DAXI (DaxiBotulinumToxinA) and how the Phase III data was compelling enough to make me open a long position in RVNC. As an investor, I think it is paramount to always fully assess any competition that...
U.S. Food and Drug Administration grants approval to Mylan Pharmaceuticals ( MYL +0.7% ) and Micro Labs for the first generics of Bristol-Myers Squibb's ( BMY -0.3% ) Eliquis (apixaban) blood thinner for two applications. More news on: Mylan N.V., Bristol-Myers Squibb Company, Health...
Quick Take Processa Pharmaceuticals ( OTCPK:PCSA ) has filed to raise $16 million in an IPO of its common stock, according to an S-1 registration statement . The firm is primarily developing a treatment for necrobiosis lipoidica, a chronic arterial disease of the limbs. PCSA is in mid-P...
The Trump administration has announced a pilot project allowing states and non-federal government entities to import certain medicines from Canada which pays much lower prices under its single-payer system. More news on: Health Care Select Sect SPDR ETF, SPDR Biotech ETF, Invesco Exchang...
Ian Read and James Kilts offer strong experience to support long-term value creation Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V. an...
Introduction In Trump's 2019 State of the Union Address, the topic of eradicating HIV morphed into a campaign promise with HIV poster child Gilead ( GILD ) getting most of the accolades due to their advances in prevention drugs. Almost 9 months later (last month), the Trump administration ...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...